Search Result

Results for "

inflammatory eye disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aryl Hydrocarbon Receptor (1) Bacterial (1) Drug Derivative (1) ERK (2) Formyl Peptide Receptor (FPR) (1) Histamine Receptor (2) Integrin (5) Interleukin Related (1) Isotope-Labeled Compounds (3) JNK (2) Keap1-Nrf2 (2) Na+/K+ ATPase (1) NF-κB (2) p38 MAPK (4) Phospholipase (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Sirtuin (2) SOD (2) TNF Receptor (1) TSH Receptor (2) VEGFR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (17) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Aryl Hydrocarbon Receptor (1)

Bacterial (1)

Drug Derivative (1)

ERK (2)

Formyl Peptide Receptor (FPR) (1)

Histamine Receptor (2)

Integrin (5)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

JNK (2)

Keap1-Nrf2 (2)

Na+/K+ ATPase (1)

NF-κB (2)

p38 MAPK (4)

Phospholipase (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

Sirtuin (2)

SOD (2)

TNF Receptor (1)

TSH Receptor (2)

VEGFR (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (17)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19344

Lifitegrast Maximum Cited Publications 11 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-N0188

Esculin 5 Publications Verification	p38 MAPK	Inflammation/Immunology Cancer
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-N0526

2"-O-Galloylhyperin 2 Publications Verification	Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD	Neurological Disease Inflammation/Immunology
2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .

HY-19344A

Lifitegrast sodium Maximum Cited Publications 11 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-172435

Rezuforimod AGN-232411; AG-80308; AGN-411	Formyl Peptide Receptor (FPR)	Neurological Disease
Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .

HY-147240

Acloproxalap ADX-629	Drug Derivative	Infection Cardiovascular Disease Inflammation/Immunology
Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes .

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-124404

12(R)-HETE	Aryl Hydrocarbon Receptor Na+/K+ ATPase Prostaglandin Receptor	Inflammation/Immunology
12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation .

HY-N0188R

Esculin (Standard)	Reference Standards p38 MAPK	Inflammation/Immunology Cancer
Esculin (Standard) is the analytical standard of Esculin. This product is intended for research and analytical applications. Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-19344R

Lifitegrast (Standard) SAR 1118 (Standard); SHP-606 (Standard)	Reference Standards Integrin	Inflammation/Immunology
Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-W281862

Sequifenadine	Histamine Receptor	Inflammation/Immunology
Sequifenadine is a H1-antihistamine. Sequifenadine has the potential for the research of inflammatory eye disease with allergic symptoms .

HY-19344S2

Lifitegrast-d4-1	Isotope-Labeled Compounds Integrin	Inflammation/Immunology
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-N0526R

2"-O-Galloylhyperin (Standard)	Reference Standards Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD	Neurological Disease Inflammation/Immunology
2"-O-Galloylhyperin (Standard) is the analytical standard of 2"-O-Galloylhyperin (HY-N0526). This product is intended for research and analytical applications. 2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

HY-N17566

Eukovoside	Bacterial Histamine Receptor	Infection Inflammation/Immunology
Eukovoside is a cinnamic acid derivative found in Euphrasia regelii with anti-inflammatory, antioxidant, antibacterial, antiallergic, and antihistamine activity. Eukovoside can be used for the research of hyperglycemic diseases, eye inflammation, upper respiratory passages inflammation, hay fever, conjunctivitis, colds, influenza, sinusitis .

HY-180939

LFA-1-IN-2	Integrin	Neurological Disease Inflammation/Immunology
LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a K_d of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease .

HY-19344S1

Lifitegrast-d6 SAR 1118-d₆; SHP-606-d₆	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4 SAR 1118-d₄; SHP-606-d₄	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0188

Esculin 5 Publications Verification	Structural Classification Monophenols other families Classification of Application Fields Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Source Classification Cancer	p38 MAPK
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-N0526

2"-O-Galloylhyperin 2 Publications Verification	Flavonols Structural Classification Classification of Application Fields Plants Flavonoids Pyrola calliantha H. Andr. Pyrolaceae Phenols Polyphenols Pyrola incarnata Fisch. ex DC. Inflammation/Immunology Disease Research Fields Source Classification	Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD
2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .

HY-N0188R

Esculin (Standard)	Structural Classification Monophenols other families Coumarins Phenols Phenylpropanoids Plants Source Classification	Reference Standards p38 MAPK
Esculin (Standard) is the analytical standard of Esculin. This product is intended for research and analytical applications. Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-N0526R

2"-O-Galloylhyperin (Standard)	Flavonols Structural Classification Flavonoids Pyrola calliantha H. Andr. Pyrolaceae Phenols Polyphenols Plants Pyrola incarnata Fisch. ex DC. Source Classification	Reference Standards Sirtuin Keap1-Nrf2 NF-κB ERK p38 MAPK JNK TSH Receptor Reactive Oxygen Species (ROS) SOD
2"-O-Galloylhyperin (Standard) is the analytical standard of 2"-O-Galloylhyperin (HY-N0526). This product is intended for research and analytical applications. 2''-O-Galloylhyperin is an active natural compound with anti‑inflammatory, antioxidant, anti‑adipogenic, antifibrotic, and cytostatic activities. 2''-O-Galloylhyperin upregulates SIRT1/Nrf2 signaling, inhibits NF-κB and MAPK (ERK1/2, p38, JNK) phosphorylation, suppresses TSHR activation, reduces ROS accumulation, and enhances SOD and GSH-Px activities. 2''-O-Galloylhyperin protects against LPS-induced tissue injury, enhances survival, and inhibits adipogenesis and fibrosis. 2"-O-Galloylhyperin can be used for the research of sepsis, acute lung injury, and thyroid eye disease .

HY-N17566

Eukovoside	Structural Classification Polysaccharides Terpenoids Sesquiterpenes Orobanchaceae Plants Euphrasia regelii Wettst. Saccharides Source Classification	Bacterial Histamine Receptor
Eukovoside is a cinnamic acid derivative found in Euphrasia regelii with anti-inflammatory, antioxidant, antibacterial, antiallergic, and antihistamine activity. Eukovoside can be used for the research of hyperglycemic diseases, eye inflammation, upper respiratory passages inflammation, hay fever, conjunctivitis, colds, influenza, sinusitis .

Cat. No.	Product Name	Chemical Structure

HY-19344S2

Lifitegrast-d4-1
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks